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Abstract
The evaluation of bone marrow of patients treated for cancer is complicated by age-related changes in the distribution
of normal (red) and fatty (yellow) marrow and by the changes induced by treatments. The treatments used in oncology
modify pathological marrow but also normal marrow and may sometimes lead to complications. The knowledge of
bone marrow physiological status and post-therapeutic patterns is important for the interpretation of marrow disorders
and effects of therapy.
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Effect of radiation on normal bone
marrow
Radiation-induced changes on normal bone
marrow
Early and late bone marrow changes after irradiation
After radiation therapy, the signal intensity of normal
bone marrow depends on the dose delivered and the
interval between the treatment and the MR study. During
the first two weeks of fractionated irradiation (after
a dose of 30 Gy) there is no definite change in the
appearance of the marrow on T1W and T2W images. On
the STIR images there is an increase in signal intensity
apparently reflecting early bone marrow oedema. After
three weeks, fatty replacement begins, the marrow shows
an increasingly heterogeneous signal and the vertebral
body shows a prominence of the signal from central
marrow fat on T1W images. Six weeks after therapy,
there are two distinct types of late marrow pattern:
homogeneous fatty replacement or a band-like pattern
(sandwich vertebral body). Marrow regeneration is more
likely to occur in children than in adults and when a
large volume of marrow is irradiated than when radiation
therapy is localised [1]. Bone marrow which received 50
Gy is definitively damaged and exhibits a fatty signal on
MR images. This pattern is due to decreased cellularity
associated with loss of bone trabeculae [2].
Changes after extensive radiation therapy
In patients who received extensive radiation therapy, the
reconversion phenomenon occurs in the non-irradiated
skeleton. Consequently, a diffuse hyposignal of normal
red marrow (T1W) should not be interpreted as diffuse
infiltration; signal intensity of this reconversion is always
greater than that of muscles.
Radiation-induced complications
Radiation therapy may cause changes in the skeletal
system depending on the age of the patient, absorbed
dose, size of the radiation field, beam energy, and
fractionation [3,4].
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Bone growth disturbances are observed after irradiation
of the immature skeleton and are greater in younger
patients and with high doses.
Osteoradionecrosis (OR) is usually diagnosed within
two to three years after treatment and appears to be dose-
related. MR imaging shows that uncomplicated OR is not
accompanied by a soft tissue mass. The differential diag-
nosis includes osteomyelitis, recurrent primary disease,
and radiation-induced second malignancies. The majority
of cases of OR occur in the mandibule, clavicle, humeral
head, ribs and femur.
Pathologic fracture and collapsed vertebral body
are frequently associated with OR. Recent collapsed
vertebral bodies show a low signal intensity on T1W
images (oedema) and therefore cannot be differentiated
from malignant infiltration. Other MR sequences are
useful to characterise a benign fracture.
Stress fractures on the sacral bone may occur after
radiation therapy for pelvic cancers.
Avascular necrosis of the femoral head is most often
associated with corticosteroid administration, but has also
been described following radiation therapy.
Radiation-induced neoplasms
Benign tumours
Osteochondroma (OC) is the most common benign
radiation-induced tumour. It occurs in children treated
by radiation therapy under the age of two years. Any
bone within the treatment field may be affected and most
lesions appear within five years of therapy. Radiation-
induced OC are histologically and radiologically identi-
cal to OC that arise spontaneously.
Radiation-induced sarcomas
Osteosarcoma is the most common type of secondary
malignant neoplasm (SMN). The radiation dose is usually
greater than 30 Gy. Children are more susceptible to
tumour induction. Radio-induced sarcomas may arise
in both pre-existing bone lesions and in normal bones
included in the radiation field. The diagnosis criteria
include a long latency period and histologically proven
sarcoma, distinct from the original lesion and arising
within the radiation field.
Effect of chemotherapy on normal bone
marrow
Chemotherapy changes on normal bone
marrow
Chemotherapy causes a myeloid depletion. The decrease
of marrow cellularity leads to an increase of fatty content:
an increased signal intensity is observed on T1W images
and a hypo-intense signal intensity on fat-suppression
sequences.
Complications of chemotherapy
Chemotherapy may be responsible for skeletal effects,
particularly methotrexate osteopathy, and ifosfamide-
induced rickets.
After intensive chemotherapy, granulocytopenic
patients can develop multifocal osteomyelitis. Bone
infarction appearing after systemic or intra-arterial
chemotherapy may mimick tumour progression [5].
Bone marrow transplantation
Knowledge of the normal MR pattern of marrow regen-
eration after transplantation may be useful in screening
for residual marrow disease, determining marrow en-
graftment, and differentiating marrow repopulation with
normal versus malignant cells.
Effect of hematopoietic growth factor
Granulocyte-colony stimulating factor (GCSF) is used to
stimulate myeloid cell production in patients undergoing
aggressive chemotherapy. It gives rise to a recolonisation
of the fatty marrow by red marrow.
The MRI changes may be diffuse or patchy; although
usually symmetrical, they may be asymmetric [6]. Aware-
ness of these findings is important to avoid false-positive
diagnosis of marrow metastases or tumour progression [7].
Effect of corticosteroı¨d
Avascular osteonecrosis is seen in patients who have
undergone bone marrow transplantation or prolongated
corticosteroid therapy, and also after radiation therapy.
The most frequently affected regions are the hips,
shoulders, and knees. MR imaging is sensitive for
detection of early ischemic necrosis.
Effects of treatments on pathologic
bone marrow
Effect of chemotherapy or radiotherapy on
bony metastases
In a large series, Brown et al. [8] reported that T1W
MR response assessment, based on changes in size
and number of vertebral metastases, accurately predicts
progression of disease in 79% of cases and stable disease
in 75% of cases. It did not predict regression of disease.
In a series of 62 affected vertebral bodies, Sugimura
et al. [9] observed a considerable diminution of lesion
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enhancement in responding lesions after irradiation or
chemotherapy.
Effect of therapy on disseminated bone marrow
involvement: lymphomas, leukaemias, myeloma
When treatment is efficient in lymphomas and
leukaemias, the signal intensity of the involved marrow
increases and the pathological enhancement after
injection of contrast medium decreases on T1W images.
In multiple myeloma, response patterns associate
normal aspects of bone marrow or persistent marrow
abnormality, without enhancement or with peripheral rim.
MR images may be helpful in monitoring the response to
treatment [10].
Conclusion
MRI is a valuable tool for the evaluation of response
under treatment and the diagnosis of bone marrow
complications. The radiologists must recognize therapy-
related changes in bone marrow and differentiate them
from recurrent disease.
Key points
Imaging characteristic patterns of treatment-induced
changes in the skeletal system allows the distinction of
complications from recurrent or metastatic disease. MR
imaging can differentiate residual disease and guide the
biopsy, and may influence the treatment.
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